316 related articles for article (PubMed ID: 26908603)
21. No correlation between NF1 mutation position and risk of optic pathway glioma in 77 unrelated NF1 patients.
Hutter S; Piro RM; Waszak SM; Kehrer-Sawatzki H; Friedrich RE; Lassaletta A; Witt O; Korbel JO; Lichter P; Schuhmann MU; Pfister SM; Tabori U; Mautner VF; Jones DTW
Hum Genet; 2016 May; 135(5):469-475. PubMed ID: 26969325
[TBL] [Abstract][Full Text] [Related]
22. Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation.
Bajenaru ML; Zhu Y; Hedrick NM; Donahoe J; Parada LF; Gutmann DH
Mol Cell Biol; 2002 Jul; 22(14):5100-13. PubMed ID: 12077339
[TBL] [Abstract][Full Text] [Related]
23. Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC/Rheb-independent manner.
Banerjee S; Crouse NR; Emnett RJ; Gianino SM; Gutmann DH
Proc Natl Acad Sci U S A; 2011 Sep; 108(38):15996-6001. PubMed ID: 21896734
[TBL] [Abstract][Full Text] [Related]
24. Mice with GFAP-targeted loss of neurofibromin demonstrate increased axonal MET expression with aging.
Su W; Xing R; Guha A; Gutmann DH; Sherman LS
Glia; 2007 May; 55(7):723-33. PubMed ID: 17348023
[TBL] [Abstract][Full Text] [Related]
25. Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in neurofibromatosis type 1.
Warrington NM; Woerner BM; Daginakatte GC; Dasgupta B; Perry A; Gutmann DH; Rubin JB
Cancer Res; 2007 Sep; 67(18):8588-95. PubMed ID: 17875698
[TBL] [Abstract][Full Text] [Related]
26. Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1.
Freret ME; Gutmann DH
J Neurosci Res; 2019 Jan; 97(1):45-56. PubMed ID: 29704429
[TBL] [Abstract][Full Text] [Related]
27. Elucidating the impact of neurofibromatosis-1 germline mutations on neurofibromin function and dopamine-based learning.
Anastasaki C; Woo AS; Messiaen LM; Gutmann DH
Hum Mol Genet; 2015 Jun; 24(12):3518-28. PubMed ID: 25788518
[TBL] [Abstract][Full Text] [Related]
28. Cerebrospinal fluid proteomic analysis reveals dysregulation of methionine aminopeptidase-2 expression in human and mouse neurofibromatosis 1-associated glioma.
Dasgupta B; Yi Y; Hegedus B; Weber JD; Gutmann DH
Cancer Res; 2005 Nov; 65(21):9843-50. PubMed ID: 16267007
[TBL] [Abstract][Full Text] [Related]
29. Defining the temporal course of murine neurofibromatosis-1 optic gliomagenesis reveals a therapeutic window to attenuate retinal dysfunction.
Toonen JA; Ma Y; Gutmann DH
Neuro Oncol; 2017 Jun; 19(6):808-819. PubMed ID: 28039362
[TBL] [Abstract][Full Text] [Related]
30. Dissecting Clinical Heterogeneity in Neurofibromatosis Type 1.
Monroe CL; Dahiya S; Gutmann DH
Annu Rev Pathol; 2017 Jan; 12():53-74. PubMed ID: 28135565
[TBL] [Abstract][Full Text] [Related]
31. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
Gottfried ON; Viskochil DH; Couldwell WT
Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
[TBL] [Abstract][Full Text] [Related]
32. Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes.
Dasgupta B; Li W; Perry A; Gutmann DH
Cancer Res; 2005 Jan; 65(1):236-45. PubMed ID: 15665300
[TBL] [Abstract][Full Text] [Related]
33. Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.
Yeh TH; Lee DY; Gianino SM; Gutmann DH
Glia; 2009 Aug; 57(11):1239-49. PubMed ID: 19191334
[TBL] [Abstract][Full Text] [Related]
34. Genotype-phenotype associations in neurofibromatosis type 1 (NF1): an increased risk of tumor complications in patients with NF1 splice-site mutations?
Alkindy A; Chuzhanova N; Kini U; Cooper DN; Upadhyaya M
Hum Genomics; 2012 Aug; 6(1):12. PubMed ID: 23244495
[TBL] [Abstract][Full Text] [Related]
35. Mice with missense and nonsense NF1 mutations display divergent phenotypes compared with human neurofibromatosis type I.
Li K; Turner AN; Chen M; Brosius SN; Schoeb TR; Messiaen LM; Bedwell DM; Zinn KR; Anastasaki C; Gutmann DH; Korf BR; Kesterson RA
Dis Model Mech; 2016 Jul; 9(7):759-67. PubMed ID: 27482814
[TBL] [Abstract][Full Text] [Related]
36. Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma.
Hegedus B; Banerjee D; Yeh TH; Rothermich S; Perry A; Rubin JB; Garbow JR; Gutmann DH
Cancer Res; 2008 Mar; 68(5):1520-8. PubMed ID: 18316617
[TBL] [Abstract][Full Text] [Related]
37. Co-occurrence of neurofibromatosis type 1 and optic nerve gliomas with autosomal dominant polycystic kidney disease type 2.
Peces R; Mena R; Martín Y; Hernández C; Peces C; Tellería D; Cuesta E; Selgas R; Lapunzina P; Nevado J
Mol Genet Genomic Med; 2020 Aug; 8(8):e1321. PubMed ID: 32533764
[TBL] [Abstract][Full Text] [Related]
38. BRAF duplications and MAPK pathway activation are frequent in gliomas of the optic nerve proper.
Rodriguez FJ; Ligon AH; Horkayne-Szakaly I; Rushing EJ; Ligon KL; Vena N; Garcia DI; Cameron JD; Eberhart CG
J Neuropathol Exp Neurol; 2012 Sep; 71(9):789-94. PubMed ID: 22892521
[TBL] [Abstract][Full Text] [Related]
39. The molecular landscape of glioma in patients with Neurofibromatosis 1.
D'Angelo F; Ceccarelli M; Tala ; Garofano L; Zhang J; Frattini V; Caruso FP; Lewis G; Alfaro KD; Bauchet L; Berzero G; Cachia D; Cangiano M; Capelle L; de Groot J; DiMeco F; Ducray F; Farah W; Finocchiaro G; Goutagny S; Kamiya-Matsuoka C; Lavarino C; Loiseau H; Lorgis V; Marras CE; McCutcheon I; Nam DH; Ronchi S; Saletti V; Seizeur R; Slopis J; Suñol M; Vandenbos F; Varlet P; Vidaud D; Watts C; Tabar V; Reuss DE; Kim SK; Meyronet D; Mokhtari K; Salvador H; Bhat KP; Eoli M; Sanson M; Lasorella A; Iavarone A
Nat Med; 2019 Jan; 25(1):176-187. PubMed ID: 30531922
[TBL] [Abstract][Full Text] [Related]
40. Temporal, spatial, and genetic constraints contribute to the patterning and penetrance of murine neurofibromatosis-1 optic glioma.
Brossier NM; Thondapu S; Cobb OM; Dahiya S; Gutmann DH
Neuro Oncol; 2021 Apr; 23(4):625-637. PubMed ID: 33080011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
